PCP
BIO icon

Perbak Capital Partners’s Bio-Rad Laboratories Class A BIO Stock Holding History

Perbak Capital Partners’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11,121
Closed -$3.37M – 309
2025
Q4 		$3.37M Buy
11,121
+2,539
+30% +$792K 1.03% 17
2025
Q3 		$2.41M Buy
8,582
+5,423
+172% +$1.48M 0.42% 24
2025
Q2 		$762K Buy
3,159
+2,234
+242% +$528K 0.17% 118
2025
Q1 		$225K Sell
925
-3,274
-78% -$985K 0.17% 170
2024
Q4 		$1.38M Buy
+4,199
New +$1.43M 0.74% 35

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Perbak Capital Partners's BIO Position: Q1 2026 in Review

Perbak Capital Partners sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2026, closing a stake of 11,121 shares — an estimated $3.37M sold.

Perbak Capital Partners first reported a position in BIO in Q4 2024 and held it in 5 quarters. The position peaked at $3.37M in Q4 2025. 394 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

  • Perbak Capital Partners reported no remaining Bio-Rad Laboratories Class A position as of Q1 2026 after selling out during the quarter.
  • Perbak Capital Partners sold 11,121 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $3.37M.
  • Perbak Capital Partners first reported a position in Bio-Rad Laboratories Class A in Q4 2024 and held it in 5 quarters.
  • Perbak Capital Partners's Bio-Rad Laboratories Class A position peaked at $3.37M in Q4 2025.
  • 394 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on Perbak Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.